Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

Status:	Recruiting
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/4/2019
Start Date:	February 16, 2018
End Date:	April 20, 2020
Contact:	Reference Study ID Number: ML40108 www.roche.com/about_roche/roche_worldwide.htm
Email:	global-roche-genentech-trials@gene.com
Phone:	+1 888-662-6728

A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy

The purpose of this study is to identify mechanisms associated with acquired immune escape by
comparing baseline and at-progression tissue samples from participants who derive clinical
benefit from CPI treatment of metastatic cancer or hematologic malignancies.

Inclusion Criteria:

- Response assessment of complete response (CR), partial response (PR), long stable
disease (SD) for >3 months with a cancer immunotherapy treatment for metastatic cancer
or hematologic malignancies either through a marketed CPI or through participation in
a Roche/Genentech CPI clinical trial.

- Availability of tumor biopsy material extracted and preserved by the investigating
site.

Exclusion Criteria:

- Participants taking CPI combination therapies with chemotherapy are not permitted.

- Pregnant, lactating, or intending to become pregnant during the study.

We found this trial at

sites

Dana-Farber Cancer Institute

450 Brookline Ave
Boston, Massachusetts 2215

617-632-3000